Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SpringWorks Therapeutics

Request full access

Clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways

New York City, United StatesFounded 2017Biotech & Life Sciences

About SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with rare diseases and cancer. The company employs a precision medicine approach, which means they tailor treatments based on the genetic and molecular profile of the disease. This approach aims to improve the efficacy and safety of treatments for underserved patient populations suffering from devastating conditions. SpringWorks operates in the biopharmaceutical market, targeting both rare diseases and oncology. Their business model involves acquiring, developing, and commercializing innovative therapies. Revenue is generated through the successful development and commercialization of these therapies, often in collaboration with other pharmaceutical companies. The company serves a niche market of patients with specific genetic profiles, offering them potentially life-changing treatments that are not widely available. SpringWorks is actively involved in clinical trials, including Phase 1b and 2 studies, to evaluate the efficacy and safety of their drug candidates.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2019

SpringWorks Therapeutics in the New York City ecosystem

Live from Dealroom

The SpringWorks Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

Series B and later8 investors entered at this stage

  • GSK
  • Perceptive Advisors
  • EcoR1 Capital
  • ArrowMark Partners
  • Deerfield
  • Samsara BioCapital
  • Boxer Capital
  • Invus
Employees mapped 352 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 32 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$26M

58 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See SpringWorks Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.